These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 30531871)

  • 1. Acquired HER2 mutations in ER
    Nayar U; Cohen O; Kapstad C; Cuoco MS; Waks AG; Wander SA; Painter C; Freeman S; Persky NS; Marini L; Helvie K; Oliver N; Rozenblatt-Rosen O; Ma CX; Regev A; Winer EP; Lin NU; Wagle N
    Nat Genet; 2019 Feb; 51(2):207-216. PubMed ID: 30531871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EGFR and HER2 hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer.
    Belli S; Esposito D; Ascione CM; Messina F; Napolitano F; Servetto A; De Angelis C; Bianco R; Formisano L
    Cancer Lett; 2024 Jul; 593():216968. PubMed ID: 38788968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
    Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J
    Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.
    Wardell SE; Ellis MJ; Alley HM; Eisele K; VanArsdale T; Dann SG; Arndt KT; Primeau T; Griffin E; Shao J; Crowder R; Lai JP; Norris JD; McDonnell DP; Li S
    Clin Cancer Res; 2015 Nov; 21(22):5121-5130. PubMed ID: 25991817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined Blockade of Activating
    Croessmann S; Formisano L; Kinch LN; Gonzalez-Ericsson PI; Sudhan DR; Nagy RJ; Mathew A; Bernicker EH; Cristofanilli M; He J; Cutler RE; Lalani AS; Miller VA; Lanman RB; Grishin NV; Arteaga CL
    Clin Cancer Res; 2019 Jan; 25(1):277-289. PubMed ID: 30314968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lasofoxifene as a potential treatment for aromatase inhibitor-resistant ER-positive breast cancer.
    Lainé M; Greene ME; Kurleto JD; Bozek G; Leng T; Huggins RJ; Komm BS; Greene GL
    Breast Cancer Res; 2024 Jun; 26(1):95. PubMed ID: 38849889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High CDK6 Protects Cells from Fulvestrant-Mediated Apoptosis and is a Predictor of Resistance to Fulvestrant in Estrogen Receptor-Positive Metastatic Breast Cancer.
    Alves CL; Elias D; Lyng M; Bak M; Kirkegaard T; Lykkesfeldt AE; Ditzel HJ
    Clin Cancer Res; 2016 Nov; 22(22):5514-5526. PubMed ID: 27252418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER
    Mao P; Cohen O; Kowalski KJ; Kusiel JG; Buendia-Buendia JE; Cuoco MS; Exman P; Wander SA; Waks AG; Nayar U; Chung J; Freeman S; Rozenblatt-Rosen O; Miller VA; Piccioni F; Root DE; Regev A; Winer EP; Lin NU; Wagle N
    Clin Cancer Res; 2020 Nov; 26(22):5974-5989. PubMed ID: 32723837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations.
    Ladd B; Mazzola AM; Bihani T; Lai Z; Bradford J; Collins M; Barry E; Goeppert AU; Weir HM; Hearne K; Renshaw JG; Mohseni M; Hurt E; Jalla S; Bao H; Hollingsworth R; Reimer C; Zinda M; Fawell S; D'Cruz CM
    Oncotarget; 2016 Aug; 7(34):54120-54136. PubMed ID: 27472462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumour kinome re-wiring governs resistance to palbociclib in oestrogen receptor positive breast cancers, highlighting new therapeutic modalities.
    Pancholi S; Ribas R; Simigdala N; Schuster E; Nikitorowicz-Buniak J; Ressa A; Gao Q; Leal MF; Bhamra A; Thornhill A; Morisset L; Montaudon E; Sourd L; Fitzpatrick M; Altelaar M; Johnston SR; Marangoni E; Dowsett M; Martin LA
    Oncogene; 2020 Jun; 39(25):4781-4797. PubMed ID: 32307447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer.
    Formisano L; Lu Y; Servetto A; Hanker AB; Jansen VM; Bauer JA; Sudhan DR; Guerrero-Zotano AL; Croessmann S; Guo Y; Ericsson PG; Lee KM; Nixon MJ; Schwarz LJ; Sanders ME; Dugger TC; Cruz MR; Behdad A; Cristofanilli M; Bardia A; O'Shaughnessy J; Nagy RJ; Lanman RB; Solovieff N; He W; Miller M; Su F; Shyr Y; Mayer IA; Balko JM; Arteaga CL
    Nat Commun; 2019 Mar; 10(1):1373. PubMed ID: 30914635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer.
    Ribas R; Pancholi S; Rani A; Schuster E; Guest SK; Nikitorowicz-Buniak J; Simigdala N; Thornhill A; Avogadri-Connors F; Cutler RE; Lalani AS; Dowsett M; Johnston SR; Martin LA
    Breast Cancer Res; 2018 Jun; 20(1):44. PubMed ID: 29880014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer.
    Brett JO; Spring LM; Bardia A; Wander SA
    Breast Cancer Res; 2021 Aug; 23(1):85. PubMed ID: 34392831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
    Shou J; Massarweh S; Osborne CK; Wakeling AE; Ali S; Weiss H; Schiff R
    J Natl Cancer Inst; 2004 Jun; 96(12):926-35. PubMed ID: 15199112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Determinants of Response to HER Kinase Inhibition in
    Smyth LM; Piha-Paul SA; Won HH; Schram AM; Saura C; Loi S; Lu J; Shapiro GI; Juric D; Mayer IA; Arteaga CL; de la Fuente MI; Brufksy AM; Spanggaard I; Mau-Sørensen M; Arnedos M; Moreno V; Boni V; Sohn J; Schwartzberg LS; Gonzàlez-Farré X; Cervantes A; Bidard FC; Gorelick AN; Lanman RB; Nagy RJ; Ulaner GA; Chandarlapaty S; Jhaveri K; Gavrila EI; Zimel C; Selcuklu SD; Melcer M; Samoila A; Cai Y; Scaltriti M; Mann G; Xu F; Eli LD; Dujka M; Lalani AS; Bryce R; Baselga J; Taylor BS; Solit DB; Meric-Bernstam F; Hyman DM
    Cancer Discov; 2020 Feb; 10(2):198-213. PubMed ID: 31806627
    [No Abstract]   [Full Text] [Related]  

  • 16. Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer.
    Kaminska K; Akrap N; Staaf J; Alves CL; Ehinger A; Ebbesson A; Hedenfalk I; Beumers L; Veerla S; Harbst K; Ehmsen S; Borgquist S; Borg Å; Pérez-Fidalgo A; Ditzel HJ; Bosch A; Honeth G
    Breast Cancer Res; 2021 Feb; 23(1):26. PubMed ID: 33602273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of the Estrogen/erbB2 Receptors Cross-talk by CDK4/6 Inhibition Triggers Sustained Senescence in Estrogen Receptor- and ErbB2-positive Breast Cancer.
    Viganò L; Locatelli A; Ulisse A; Galbardi B; Dugo M; Tosi D; Tacchetti C; Daniele T; Győrffy B; Sica L; Macchini M; Zambetti M; Zambelli S; Bianchini G; Gianni L
    Clin Cancer Res; 2022 May; 28(10):2167-2179. PubMed ID: 35254385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6 Inhibition and Endocrine Therapy in Advanced HR
    Sammons S; Shastry M; Dent S; Anders C; Hamilton E
    Clin Breast Cancer; 2020 Feb; 20(1):1-11. PubMed ID: 31780379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fulvestrant induces resistance by modulating GPER and CDK6 expression: implication of methyltransferases, deacetylases and the hSWI/SNF chromatin remodelling complex.
    Giessrigl B; Schmidt WM; Kalipciyan M; Jeitler M; Bilban M; Gollinger M; Krieger S; Jäger W; Mader RM; Krupitza G
    Br J Cancer; 2013 Nov; 109(10):2751-62. PubMed ID: 24169358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1.
    Berger F; Marce M; Delaloge S; Hardy-Bessard AC; Bachelot T; Bièche I; Pradines A; De La Motte Rouge T; Canon JL; André F; Arnould L; Clatot F; Lemonnier J; Marques S; Bidard FC;
    BMJ Open; 2022 Mar; 12(3):e055821. PubMed ID: 35241469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.